Study guide
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses
Key Takeaways Explain This Topic AI
Superoxide and hydrogen peroxide are precursors; the hydroxyl radical from Fenton chemistry with iron or copper damages DNA, lipid, and protein at the metal-binding site, and peroxynitrite forms when nitric oxide meets superoxide.
SOD converts superoxide to hydrogen peroxide; catalase and glutathione peroxidase remove peroxide; GSH and the Nrf2/Keap1 ARE battery are the inducible thiol and electrophile defenses.
Lipid peroxidation of polyunsaturated fatty acids and 8-oxo-dG in DNA are workhorse oxidative-injury markers; neither marker by itself is an organism-level adverse outcome.
Transcriptomics, proteomics, and metabolomics are tools for testing a stated ROS hypothesis (handbook II.1 F, II.6 E) and need enzyme, knockout, or pathology follow-up.
GSTM1-null genotype, CYP2E1 induction or knockout, and Nrf2 or SOD2 loss are susceptibility examples (II.3); paraquat, carbon tetrachloride, and doxorubicin illustrate distinct ROS architectures.
Last updated: September 2026
Why oxidative stress is a Domain II mechanism skill
Handbook II.1 asks you to develop a mechanistic hypothesis and to know established molecular pathways, organ physiology, genetic-variant phenotypes (knockouts and SNPs), and when omics is an appropriate test of that hypothesis ( II.1 A–F ). Handbook II.3 asks which attributes— genetic polymorphisms , life-stage , sex , and background disease —change susceptibility. Independent ExamFinch material in this section treats reactive oxygen species (ROS) and reactive nitrogen species (RNS) as a working example of that skill, not as a slogan you write on every unexplained lesion. This chapter is not an ABT product and does not claim official approval, review, or partnership with ABT.
A ROS story is complete only when you can name the initiating oxidant , the metal or enzyme that converts it , the macromolecule that is damaged , the defense that failed or was induced , and the in-life or anatomic outcome . “Oxidative stress” written into a report without those pieces is a label, not a mechanism.
II.1 A–B are the experimental craft. Start from an apical effect (centrilobular necrosis, delayed pulmonary fibrosis, dilated cardiomyopathy). Propose a molecular initiating chemistry (CYP2E1 reductive dehalogenation, redox cycling, Fenton iron). Test it in vitro (isolated mitochondria, primary hepatocytes, ARE-luciferase reporters, iron chelation, CYP2E1 inhibition) and in vivo (time course of GSH before necrosis, CYP2E1 knockout or induction, Nrf2-null challenge, metabolite identification). Omics enter only after that hypothesis exists ( II.1 F ).
Superoxide, hydrogen peroxide, hydroxyl radical, and peroxynitrite
Molecular oxygen accepts electrons one at a time. The first product is superoxide (O2•−) . Sources you should be able to name include the mitochondrial electron-transport chain (especially complex I and complex III when the chain is over-reduced or blocked), NADPH oxidases (NOX) , xanthine oxidase , and one-electron reduction of redox-cycling xenobiotics. Superoxide is a modest one-electron reductant and a precursor. It does not wander the nucleus oxidizing random guanines the way hydroxyl radical does.
Copper/zinc superoxide dismutase (SOD1) in cytosol, manganese SOD (SOD2) in the mitochondrial matrix, and extracellular SOD (SOD3) convert two superoxide anions to hydrogen peroxide (H2O2) and oxygen: 2 O2•− + 2 H+ → H2O2 + O2. H2O2 is not a free radical . It crosses membranes more readily than superoxide, supports physiologic signaling at low flux, and becomes injurious when it meets redox-active iron or copper .
The Fenton reaction is Fe2+ + H2O2 → Fe3+ + •OH + OH−. Copper(I) does the analogous chemistry. The hydroxyl radical (•OH) reacts at diffusion-limited rates with DNA, protein, and lipid at the site where the metal is bound . That is why loosely chelatable iron and copper are not trivia: they localize the lesion. Superoxide can reduce Fe3+ back to Fe2+ (a Haber–Weiss cycle), so a catalytic metal plus a modest peroxide flux is enough to keep producing hydroxyl radical.
Nitric oxide (NO•) from nitric-oxide synthases combines with superoxide at a near-diffusion-limited rate to form peroxynitrite (ONOO−) . Peroxynitrite and its conjugate acid nitrate protein tyrosines ( 3-nitrotyrosine ), oxidize thiols, and can yield hydroxyl-like oxidants. RNS injury is what happens when NO production and superoxide production occupy the same compartment—not a separate universe from ROS.
Antioxidant defenses: SOD, catalase, GPx, GSH, and Nrf2/Keap1
Catalase in peroxisomes converts 2 H2O2 → 2 H2O + O2 and matters most at high peroxide concentrations. Glutathione peroxidases (GPx) , several of them selenoproteins, reduce H2O2 and lipid hydroperoxides using reduced glutathione (GSH) : H2O2 + 2 GSH → 2 H2O + GSSG . Glutathione reductase then uses NADPH to regenerate GSH. Drain NADPH—as paraquat does while it redox-cycles—and the GSH cycle stalls even if the tripeptide is still present on a bulk assay.
GSH is γ-glutamyl-cysteinyl-glycine. Hepatocytes hold it in the millimolar range. Rate-limiting synthesis is glutamate-cysteine ligase (GCLC/GCLM) . GSH conjugates electrophiles via glutathione S-transferases (GSTs) and keeps protein thiols reduced. A fall in the GSH:GSSG ratio is a redox readout. It is not, by itself, an adverse outcome.
Nrf2 (NFE2L2) is the inducible transcriptional defense against electrophiles and oxidants. Under basal conditions Keap1 binds Nrf2 and presents it to a Cul3 ubiquitin ligase, so Nrf2 is degraded. Oxidative or electrophilic modification of Keap1 cysteines (classically Cys151, Cys273, and Cys288) impairs that degradation. Nrf2 accumulates, heterodimerizes with small Maf proteins, and binds antioxidant response elements (AREs) . Induced genes include heme oxygenase-1 (HMOX1) , NAD(P)H:quinone oxidoreductase 1 (NQO1) , GCLC, many GSTs, and thioredoxin-system components. A chemical that both generates ROS and induces Nrf2 is the expected adaptive loop, not a contradiction. Nrf2-null animals convert a borderline oxidant stress into frank injury—the knockout half of II.1 E .
Lipid peroxidation and 8-oxo-dG
Polyunsaturated fatty acids (PUFAs) have bis-allylic hydrogens that hydroxyl radical or lipid oxyl radicals abstract. The carbon-centered radical adds oxygen to a lipid peroxyl radical , which abstracts a hydrogen from a neighboring PUFA— chain propagation . Termination and decomposition yield malondialdehyde (MDA) , 4-hydroxynonenal (4-HNE) , and, more specifically, F2-isoprostanes . Membranes lose order; proteins and DNA acquire carbonyl and aldehyde adducts; mitochondrial inner membrane damage feeds the permeability-transition story in section 8.2.
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) (also written 8-OHdG) is the workhorse oxidative DNA lesion at guanine C8. It mispairs with adenine and produces G→T transversions if unrepaired. OGG1 base-excision repair removes it. Urinary 8-oxo-dG is used in biomonitoring; artifactual oxidation during DNA work-up is a famous pitfall. A single 8-oxo-dG number without a second marker or pathology is a weak standalone claim.
Omics as hypothesis tools (II.1 F, II.6 E)
Transcriptomics (microarray or RNA-seq) can show an Nrf2-class signature, a p53 DNA-damage signature, or a hypoxic HIF signature. It reports mRNA , not enzyme activity and not that the animal is clinically injured. Proteomics can add abundance and some post-translational marks (protein carbonyls, 3-nitrotyrosine peptides). Metabolomics sits closer to phenotype: GSH/GSSG, NADPH, lipid-peroxidation products, TCA intermediates.
Handbook II.1 F is the decision to apply omics to test a stated hypothesis (“if this is CYP2E1-dependent lipid peroxidation, then CYP2E1 protein, F2-isoprostanes, and an Nrf2 transcript battery should move before necrosis”). Handbook II.6 E —picked up again in section 8.3—is the translation rule: an omics pattern is not an organism-level effect until you connect it to function, histopathology, or a population outcome. Use enrichment to design the next experiment (SOD2 heterozygote, iron chelation, CYP2E1 inhibition), not as the last sentence of a risk conclusion.
Genetic variants, knockouts, and SNPs as susceptibility (II.3)
GSTM1*0 is a common homozygous gene deletion . GSTM1-null individuals make no GSTM1 protein. For some electrophilic metabolites (certain polycyclic aromatic hydrocarbon diol-epoxides), that can increase adduct burden. For other substrates another GST isoform compensates. Do not treat “GSTM1-null equals universally sensitive” as a law.
CYP2E1 oxidizes ethanol, acetone, benzene, chloroform, and carbon tetrachloride . Published CYP2E1 SNPs, including the well-studied 5′-flanking RsaI c2 allele, have inconsistent human epidemiology. The clearer susceptibility story is phenotypic induction : chronic ethanol, fasting, acetone, and poorly controlled diabetes increase CYP2E1 protein and can potentiate zone-3 bioactivation. CYP2E1-null mice are protected from classic CCl4 necrosis—the experimental converse.
SOD2 heterozygosity increases mitochondrial oxidative injury without requiring a xenobiotic. Life-stage changes neonatal GSH and CYP ontogeny. Sex changes hormonal regulation of CYPs and, in the male rat, the α2u-globulin load taught in section 8.3. Background disease —fatty liver, hemochromatosis increasing catalytic iron—completes the II.3 attribute list. A polymorphism is a hypothesis about susceptibility, not a default uncertainty factor.
Worked ROS toxicants: paraquat, carbon tetrachloride, doxorubicin
Paraquat (1,1′-dimethyl-4,4′-bipyridinium) accepts an electron from NADPH-dependent reductases to a radical cation, then donates that electron to oxygen, regenerating the parent dication and superoxide — futile redox cycling . Alveolar epithelium concentrates paraquat via the polyamine uptake system (shared with putrescine and spermidine). NADPH and GSH collapse locally. The clinical picture is delayed, progressive pulmonary fibrosis . The mechanism is not CYP2E1 bioactivation and is not a liver-zonation story.
Carbon tetrachloride is the opposite architecture. Hepatic CYP2E1 in zone 3 reductively dehalogenates CCl4 to the trichloromethyl radical (•CCl3) . Low centrilobular oxygen tension favors that reductive path. •CCl3 adds oxygen to CCl3OO• and starts lipid peroxidation and centrilobular necrosis. Ethanol induction of CYP2E1 potentiates CCl4—a mixture term you will name formally in section 8.3. Vitamin E status and GSH tone modify severity; they do not rewrite the initiating enzyme.
Doxorubicin has a quinone that undergoes one-electron reduction (NADPH-cytochrome P450 reductase; mitochondrial NADH dehydrogenase) to a semiquinone that redox-cycles to superoxide. Iron catalyzes hydroxyl-radical formation. Cardiomyocytes are mitochondrion-rich and catalase-poor, which is why the heart is the ROS-target organ in this story. A second, on-target mechanism—poisoning of topoisomerase IIβ (TOP2B) in cardiomyocytes—also explains delayed dilated cardiomyopathy. On an item, say which data would distinguish redox cycling (iron chelation, SOD mimics, lipid peroxidation) from TOP2B (enzyme engagement and DNA-break markers that do not require catalytic iron). Cumulative, delayed cardiomyopathy is the clinical package; do not collapse it to “the drug is a general ROS generator in every organ.”
- Agent or node Initiating chemistry Principal defense or modifier Typical target story
- Superoxide One-electron reduction of O2 SOD1/2/3 to H2O2 Precursor from mitochondria, NOX, or redox cyclers
Hydrogen peroxide SOD product; oxidases Catalase; GPx plus GSH Signaling at low flux; Fenton substrate at metals
Hydroxyl radical Fenton (Fe2+ or Cu+) Keep metals bound; limit H2O2 Site-of-generation DNA, lipid, and protein lesions
- Peroxynitrite NO• plus O2•− Limit co-production of both radicals 3-nitrotyrosine; thiol oxidation
- Paraquat Redox cycle to O2•−; NADPH drain Polyamine-transporter uptake; GSH/NADPH Delayed pulmonary fibrosis
Carbon tetrachloride CYP2E1 to •CCl3 / CCl3OO• CYP2E1 amount; GSH and vitamin E context Centrilobular lipid peroxidation and necrosis
Doxorubicin Quinone redox cycle plus iron; also TOP2B Low cardiac catalase; iron status Cumulative dilated cardiomyopathy
- GSTM1-null Missing one GST isoform Other GSTs may compensate Substrate-specific electrophile susceptibility
- Nrf2/Keap1 ARE gene battery Keap1 cysteine sensors Inducible defense; knockout increases injury
- Scenario
A solvent study shows centrilobular necrosis, increased F2-isoprostanes, early GSH depletion, and a transcriptomic Nrf2 signature in wild-type mice, with worse necrosis after ethanol pretreatment and protection by a CYP2E1 inhibitor. That package is CYP2E1-dependent radical lipid peroxidation . A paraquat study with polyamine-transporter-dependent alveolar uptake, NADPH collapse, and fibrosis without a CYP2E1 requirement is redox cycling in lung . Calling both “ROS toxicity” erases the mechanism Domain II is testing. A third cohort’s RNA-seq heat map lights Nrf2 genes at a dose with normal histopathology and normal liver function: that is an adaptive transcript hypothesis , not an organism-level adverse outcome ( II.6 E ).
Traps
Treating hydrogen peroxide as a free radical.
Forgetting that hydroxyl radical hits where iron or copper sits, not at a distant receptor.
Using a lone 8-oxo-dG value or a heat map as an adverse outcome.
Equating GSTM1-null with universal chemical sensitivity.
Assigning paraquat to CYP2E1, or carbon tetrachloride to the polyamine transporter.
Treating every doxorubicin injury as redox cycling while ignoring TOP2B, or the reverse.